$ABOS

12 Health Care Stocks Moving In Monday's Pre-Market Session

This article lists 12 healthcare stocks experiencing significant movement in Monday's pre-market session. It highlights both gainers and losers, providing their current stock prices, percentage changes, and market capitalizations. Companies like Acumen Pharmaceuticals and Dermata Therapeutics saw gains, while 60 Degrees Pharmaceuticals and Revolution Medicines experienced declines.

Original reporting
Benzinga · Benzinga Insights, Benzinga Staff Writer
Published Jan 26, 2026, 12:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 26, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
12 Health Care Stocks Moving In Monday's Pre-Market Session — source image
Decision brief

The 30-second read

$ABOSBullishMed
01

Why it matters

Pre-market activity suggests increased trader interest and potential volatility in the healthcare sector.

02

Market read

The movements reflect sector-specific dynamics, with potential implications for related healthcare stocks.

03

What to watch

Broader market conditions and sector news could influence stock performance beyond pre-market indicators.

Relevance 6/10Timing: Immediate; pre-market movements can influence intraday trading decisions.

Background

The article reports significant pre-market movements in 12 healthcare stocks, highlighting both gainers and losers, which can influence intraday trading strategies.

Company-level read

Ticker impact

$ABOSBullishHigh confidence
Context

High relevance due to bullish sentiment and significant pre-market movement.

Expected impact

Moderate increase in stock price expected during the trading session.

Evidence & confidence

The bullish sentiment score of 0.518226 and pre-market gains suggest strong buying interest, supported by positive industry trends.

Market effects

The healthcare sector may experience increased volatility due to pre-market movements, potentially affecting related stocks.

Limited regional impact; movements are specific to individual stocks.

Minimal; sector-specific news with limited global implications.

Counterpoint

Pre-market gains may be temporary; a reversal could occur during regular trading hours due to profit-taking or sector rotation.

Key entities

  • Acumen Pharmaceuticals

    A biotech company focusing on rare disease therapeutics.

  • Dermata Therapeutics

    A clinical-stage dermatology-focused biotech.

  • 60 Degrees Pharmaceuticals

    A pharmaceutical firm experiencing declines in pre-market trading.

  • Revolution Medicines

    A biotech company with recent stock declines.

Related articles

$ABOSMed

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results

Acumen Pharmaceuticals, Inc. (ABOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights • Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 • Two cand

$BHPLow

BHP's Copper Production Falls 19% Amid Chilean Storms, Yet Annua

BHP Group reported a 19% drop in copper production due to Chilean storms and lower ore grades, but maintained annual guidance. The company has a 4.24% dividend yield, though its stock is 31.0% overvalued according to GF Value™. BHP's GF Score™ is 72/100, reflecting strong financials and profitability but weak growth. Insiders have sold shares, and guru activity is mixed.

$TSLAMed

Tesla Dec. 3 Vote: Musk's 3-Year Term at Stake [2026]

Tesla has scheduled a December 3, 2026, shareholder vote to re-elect Elon Musk, Robyn Denholm, and JB Straubel to its board. The vote is seen as a referendum on Tesla's hardware-focused future, including humanoid robots and autonomous ride-hailing. Shareholders will also vote on executive pay and auditor ratification. The board emphasizes continuity amid Tesla's shift towards non-car revenue sources.